Cutaneous responses to human C 3  anaphylatoxin in man.
D001706:Biopsy; D002465:Cell Movement; D003165:Complement System Proteins / Q000494:pharmacology*; D004890:Erythema / Q000209:etiology / Q000517:prevention & control; D006632:Histamine / Q000494:pharmacology; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D007249:Inflammation / Q000209:etiology / Q000517:prevention & control; D007271:Injections, Intradermal; D008012:Lidocaine; D008407:Mast Cells / Q000187:drug effects; D009504:Neutrophils; D010323:Passive Cutaneous Anaphylaxis; D010447:Peptide Hydrolases / Q000627:therapeutic use; D010455:Peptides / Q000494:pharmacology*; D011537:Pruritus / Q000209:etiology; D012867:Skin / Q000098:blood supply / Q000187:drug effects* / Q000473:pathology; D013997:Time Factors; D014118:Toxins, Biological / Q000494:pharmacology*
D006634:Histamine H1 Antagonists; D010455:Peptides; D014118:Toxins, Biological; D006632:Histamine; D003165:Complement System Proteins; D008012:Lidocaine; D010447:Peptide Hydrolases